Swedish private equity firm Innoventus has unveiled its first product to invest in biotechnology.

The Innoventus Life Science fund is hoping to raise Skr600m (€65.7m) within 12 months, said Hans Andréasson, managing director of Innoventus. The fund has already secured 50% of its capital from Swedish institutions such as A-P Fonden 4 and 6.